UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE

UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE

Show other versions (1)

<p>Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel) use in patients having appropriate indications according to current clinical guidelines and to study the possibility of prescription rate improvement by education activity directed to doctors...

Full description

Bibliographic Details
Main Authors:	S. Yu. Martsevich, V. P. Voronina, M. L. Ginzburg, N. P. Kutishenko, Yu. N. Polyanskaya, T. G. Kheliya, A. M. Malysheva, S. N. Tolpygina, V. S. Kutuzova, E. A. Gofman, A. D. Deev
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-12-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	антиагреганты клопидогрел оригинальный лекарственный препарат воспроизведенный лекарственный препарат двойная антиагрегантная терапия
Online Access:	http://www.rpcardio.ru/jour/article/view/540

Similar Items

THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY
by: V. V. Yakusevich, et al.
Published: (2016-01-01)

THE ROLE OF THE SCIENTIFIC OVERVIEWS IN THE GENERIC DRUG REGISTRATION PROCESS IN THE RUSSIAN FEDERATION AND EURASIAN ECONOMIC UNION
by: K. S. Milchakov
Published: (2019-01-01)

PHARMACEUTICAL DEVELOPMENT OF DRUGS FOR PEDIATRIC PRACTICE: FUNDAMENTAL BASES AND SPECIFIC FEATURES
by: I. A. Narkevich, et al.
Published: (2019-01-01)

The approaches to the assessment of biosimilarity of biotechnological preparations: quality issues
by: A. N. Mironov, et al.
Published: (2018-02-01)

THE KARDIOKANON STUDY: A WAY TO SETTLE THE SUBJECT OF CLINICAL EQUIVALENCE OF GENERIC AND ORIGINAL DRUGS
by: S. Yu. Martsevich, et al.
Published: (2015-12-01)

ASSESSMENT OF THERAPEUTICAL EQUIVALENCY OF ORIGINAL AND GENERIC INDAPAMIDE IN HYPERTENSIVE PATIENTS BY RANDOMIZED CROSS-OVER STUDY
by: N. P. Kutishenko, et al.
Published: (2015-12-01)

ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS
by: N. A. Dmitrieva, et al.
Published: (2016-01-01)

STATIN GENERICS: EFFICACY AND SAFETY RATIO
by: V. P. Voronina, et al.
Published: (2016-01-01)

DEVELOPMENT AND REGISTRATION OF A COMBINED DRUG FOR THE TREATMENT OF HIV INFECTION ON THE BASIS OF ON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) PHOSPHAZIDE AND LAMIVUDINE
by: A. F. Khohlov, et al.
Published: (2019-01-01)

THE PROBLEMS ASSOCIATED WITH SWITCHING BRAND-NAME ANTIEPILEPTIC DRUGS TO GENERICS: A FOCUS ON TOPAMAX: A REVIEW OF LITERATURE AND A CASE REPORT
by: K. Yu. Mukhin, et al.
Published: (2016-08-01)

Guidelines for the planning and implementation of pharmacovigilance systems audit
by: S. V. Glagolev, et al.
Published: (2018-02-01)

Bisoprolol medications in a comparative study on effectiveness and tolerability of original agent and its generic in patients with mild to moderate arterial hypertension
by: S. Yu. Martsevich, et al.
Published: (2007-12-01)

THE PROBLEM OF MEDICINES INTERCHANGEABILITY. FOCUS ON PERINDOPRIL
by: A. I. Malyhina, et al.
Published: (2015-09-01)

Выбор препарата для лекарственной терапии с учетом особенностей субстанции
by: С. С. Вялов, et al.
Published: (2012-08-01)

COMPARATIVE EVALUATION OF EFFICACY AND TOLERABILITY OF ORIGINAL AND GENERIC BISOPROLOL IN PATIENTS WITH ARTERIAL HYPERTENSION 1-2 GRADE
by: S. N. Tolpygina, et al.
Published: (2015-12-01)

DRUGS DEVELOPED AT «ARC BASS» WITH M.D. MASHKOVSKII LEAD (REVIEW)
by: S. Ya. Skachilova, et al.
Published: (2019-02-01)

DEVELOPMENT OF METHOD FOR DETERMINATION OF INTRINSIC VISCOSITY OF INJECTABLE DRUG WITH CHONDROITIN SULFATE
by: K. R. Saveleva, et al.
Published: (2019-01-01)

GELS FOR ORAL ADMINISTRATION. PART 1. MEDICAL PRODUCTS AND DIETARY SUPPLEMENTS (REVIEW)
by: E. Y. Zagorulko, et al.
Published: (2019-01-01)

TREATMENT OF COUGH IN FREQUENTLY ILL CHILDREN WITH ACUTE RESPIRATORY TRACT INFECTIONS
by: A.I. Safina
Published: (2014-01-01)

CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC AMLODIPINE IN PATIENTS WITH MILD-TO-MODERATE ARTERIAL HYPERTENSION
by: N. A. Belolipetskiy, et al.
Published: (2015-12-01)

THE LABELLING OF THE CONTAINERS FOR STORAGE AND TRANSPORTATION OF MEDICINAL PRODUCTS
by: A. P. Pereverzev, et al.
Published: (2018-02-01)

Pharmaceutical Development of «Sedoflav» Capsules, Standardization and Validation of Flavonoids Assay Methods
by: M. A. Dzhavakhyan, et al.
Published: (2020-08-01)

Bisoprolol in cardiovascular disease treatment
by: S. N. Tolpygina, et al.
Published: (2008-12-01)

On the issue of assessing the quality of preservatives used in current practice of immunobiological preparations production
by: V. P. Bondarev, et al.
Published: (2018-02-01)

Guidelines for the Preparation of a Document Containing the Drug Safety Monitoring Results
by: Yu. V. Olefir, et al.
Published: (2018-02-01)

MAMMOGRAPHIC DENSITY AS A CRITERION OF THE EFFICIENCY OF TREATMENT OF BENIGN BREAST DISEASE AND REDUCING RISK OF BREAST CANCER
by: V. G. Bespalov, et al.
Published: (2017-06-01)

Russian military pharmacopoeias in the military health system
by: Yu. V. Miroshnichenko, et al.
Published: (2018-02-01)

TREATMENT EFFECTIVENESS AND SAFETY OF THE ORIGINAL AND GENERIC BISOPROLOL IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: E. I. Tarlovskaya, et al.
Published: (2015-12-01)

A COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF GENERIC AND ORIGINAL LOW-DOSE BISOPROLOL/HYDROCHLOROTHIAZIDE COMBINATION IN PATIENTS WITH ARTERIAL HYPERTENSION OF 1-2 DEGREES. RESULTS OF CLINICAL RANDOMIZED CROSSOVER STUDY
by: S. Yu. Martsevich, et al.
Published: (2015-09-01)

TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER (PART 2)
by: S. N. Tolpygina, et al.
Published: (2015-09-01)

HAVE WE SHIFTED OUR PARADIGM OF CLOPIDOGREL AS A MANDATORY DRUG IN TREATMENT OF CARDIOLOGICAL PATIENTS AFTER THE INTRODUCTION OF MORE POWERFUL ANTIAGREGANTS?
by: E. P. PANCHENKO
Published: (2017-12-01)

Perfection of management principles by the safety signals of medicinal products
by: B. K. Romanov, et al.
Published: (2018-02-01)

Choosing a systemic antifungal agent for the treatment of vaginal candidiasis: original or generic fluconazole?
by: А. S. Dukhanin
Published: (2015-12-01)

The revision of the restrictive lists of medicinal products
by: B. K. Romanov, et al.
Published: (2018-02-01)

INDIVIDUAL APPROACH TO PATIENTS WITH INDICATION FOR ANTIPLATELET THERAPY. WHAT TO RELY ON IN CHOOSING THE THERAPY?
by: N. V. LOMAKIN, et al.
Published: (2017-12-01)

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

Therapeutic Drug Monitoring of Antibiotics Is Needed in the Treatment of Sepsis
by: G. P. Plotnikov, et al.
Published: (2022-12-01)

ACHIEVEMENT OF TARGET BLOOD PRESSURE LEVEL IN HYPERTENSIVE PATIENTS WITH AMLODIDINE: ORIGINAL DRUG VERSUS GENERIC
by: S. Yu. Martsevich, et al.
Published: (2016-01-01)

Środki wspomagające w treningu siłowym
by: Konrad Kraszewski
Published: (2016-12-01)

Double antiplatelet therapy in patients with acute coronary syndrome
by: A. V. Rodionov, et al.
Published: (2011-10-01)